Sm Ab ELISA Kit

Catalog Number KA1112

96 assays

Version: 03

Intended for research use only

Table of Contents

Introduction

Intended Use

This kit is a test system for the quantitative measurement of IgG class autoantibodies against Sm in human serum or plasma. This product is intended for research use only.

Background

The detection of autoantibodies against Sm proteins is a component of the multi-parametric ACR criteria for the diagnosis of systemic lupus erythematous (SLE). The detection of Sm antibodies serves as a prognostic marker for SLE, there is a relationship between the appearance of Sm antibodies and severe organ manifestations of the disease. Evaluation of a test result should always take into account all clinical and laboratory diagnostic findings.

Principle of the Assay

Highly purified Sm is bound to microwelis.
The determination is based on an indirect enzyme linked immune reaction with the following steps:
Specific antibodies in the sample bind to the antigen coated on the surface of the reaction wells. Alter Incubation, a washing step removes unbound and unspecifically bound serum or plasma components. Subsequently added enzyme conjugate binds to the immobilized antibody-antigen-complexes. After incubation, a second washing step removes unbound enzyme conjugate. After addition of substrate solution the bound enzyme conjugate hydrolyses the substrate forming a blue coloured product. Addition of an acid stops the reaction generating a yellow end-product. The intensity of the yellow color correlates with the concentration of the antibody-antigen-complex and can be measured photometrically at 450 nm.

General Information

Materials Supplied

List of component

Component	Amount
1x divisible microplate consisting of 12 modules of 8 wells each. Ready to use. Color code on module.	96 wells
Calibrator A-F (0, 12.5, 25, 50, 100, 200 U/mL), containing serum/buffer matrix (PBS BSA, detergent, NaN3 0.09%), yellow. Ready to use.	1.5 mL x 6
Control positive (1) and negative (2), containing Sm antibodies in a serum/buffer matrix (PBS, SSA, detergent, NaN3 0.09%), yellow. Ready to use. The concentration is specified on the certificate of analysis.	1.5 mL x 2
Sample Buffer, containing PBS, BSA, detergent, preservative sodium azide 0.09% yellow, concentrate (5x)	20 mL
Enzyme Conjugate, containing anti-human lgG antibodies, HRP labelled; PBS BSA detergent, preservative Proclin 0.05%, light red. Ready to use.	15 mL
TMB substrate, containing 3,3',5,5'-Tetramethylbenzidin, colorless. Ready to use.	15 mL
Stop solution: contains acid. Ready to use.	15 mL
Wash Buffer: Containing Tris, detergent, preservative sodium azide 0.09%; 50x concentrated.	20 mL

Storage Instruction

✓ Store test kit at 2-8°C in the dark.

✓ Do not expose reagents to heat, sun or strong light during storage and usage.

✓ Store microplate sealed and desiccated in the clip bag provided.

✓ Unopened reagents are stable until expiration of the kit. See labels for individual batch.

✓ Diluted Wash Solution and Sample Buffer are stable for at least 30 days when stored at 2-8°C. We recommend consumption on the same day.

Materials Required but Not Supplied

✓ Microplate reader capable of endpoint measurements at 450 nm; optional; reference filter at 620 nm.

✓ Data reduction software.

✓ Multi-channel dispenser or repeatable pipette for 100 µL.

✓ Vortex mixer.

✓ Pipettes for 10 µL, 100 µL and 1000 µL.

✓ Laboratory timing device.

✓ Distilled or deionized water.

- ✓ Measuring cylinder for 1000 mL and 100 mL.
- ✓ Plastic container for storage of the wash solution.
- ✓ This ELISA assay is suitable for use on open automated ELISA processors. Each assay has to be validated on the respective automated system.

Precautions for Use

- ✓ Warnings and Precautions
1. All reagents of this kit are intended for research use only.
2. Components containing human serum were tested and found negative for HBsAg, HCV, HIV1 and HIV2 by FDA approved methods. No test can guarantee the absence of HBsAg, HCV, HIV1 or HIV2, and so all human serum based reagents in this kit must be handled as though capable of transmitting infection.
3. Bovine serum albumin (BSA) used in components has been tested for BSE and found negative.
4. Avoid contact with substance TMB (3,3',5,5'-Tetramethyl-benzidine).
5. Stop solution contains acid, classification is non-hazardous. Avoid contact with skin.
6. Controls, Calibrators, Sample Buffer and Wash Solution contain sodium azide 0.09% as preservative. This concentration is classified as non-hazardous.
7. Enzyme conjugate contains ProClin 300 0.05% as preservative. This concentration is classified as non-hazardous.
8. During handling of all reagents, controls, and serum samples observe the existing regulations for laboratory safety regulations and good laboratory practice.
9. First aid measures: In case of skin contact, immediately wash thoroughly with water and soap. Remove contaminated clothing and shoes and wash before reuse. If system fluid comes into contact with skin, wash thoroughly with water. After contact with the eyes carefully rinse the opened eye with running water for at least 10 minutes. Get medical attention if necessary.
10. Personal precautions, protective equipment and emergency procedures.
11. Observe laboratory safety regulations. Avoid contact with skin, and eyes. Do not swallow. Do not pipette by mouth. Do not eat, drink, smoke or apply makeup in areas where specimens or kit reagents are handled. When spilled, absorb with an inert material and put the spilled material in an appropriate waste disposal.
12. Wear protective glasses. Used according to intended use no dangerous reactions known.
13. Conditions to avoid: Since substrate solution is light-sensitive. Store in dark.
14. For disposal of laboratory waste the national or regional legislation has to be observed.
15. Observed the guidelines for performing quality control in medical laboratory by assaying control sera.

- ✓ Procedure Notes
1. Do not use kit components beyond their expiration dates.
2. Do not interchange kit components from different lots and products.
3. All materials must be at room temperature (20-28°C) prior to use.

4. Prepare all reagents and samples. Once started, perform the test without interruption.

5. Double determinations may be done. By this means pipetting errors may become obvious.

6. Perform the assay steps only in the order indicated.

7. Always use fresh sample dilutions.

8. Pipette all reagents and samples into the bottom of the wells.

9. To avoid carryover or contamination, change the pipette tip between samples and different kit controls.

10. Wash microwells thoroughly and remove the last droplets of Wash buffer.

11. All incubation steps must be accurately timed.

12. Do not re-use microplate wells.

Assay Protocol

Reagent Preparation

✓ Wash Solution

Dilute the contents of one vial of the buffered wash solution concentrate (50x) with distilled or deionized water to a final volume of 1000 mL prior to use.

✓ Sample Buffer

Prior to use dilute the contents (20 mL) of one vial of the sample buffer 5x concentrate with distilled or deionised water to a final volume of 100 mL.

Sample Preparation

✓ Specimens collection, storage and handling

- Collect whole blood specimens using acceptable techniques to avoid hemolysis.
- Allow blood to clot and separate the serum or plasma by centrifugation.
- Test serum should be clear and non-hemolyzed. Contamination by hemolysis or lipemia should be avoided, but does not interfere with this assay.
- Specimens may be refrigerated at 2-8°C for up to five days or stored at -20°C up to six months.
- Avoid repetitive freezing and thawing of serum or plasma samples. This may result in variable loss of antibody activity.
- Testing of heat-inactivated sera is not recommended.

✓ Preparation of samples

Dilute samples 1:100 before assay. Put 990 µL of prediluted sample buffer in a polystyrene tube and add 10 µL of sample. Mix well.

Note: Calibrators/Controls are ready to use and need not be diluted.

Assay Procedure

1. Prepare enough microplate modules for all calibrators / controls and samples.
2. Pipette 100 µL of calibrators, controls and prediluted samples into the wells.
3. Incubate for 30 minutes at room temperature (20-28°C).
4. Discard the contents of the microwells and wash 3 times with 300 µL of wash solution.
5. Dispense 100 µL of enzyme conjugate into each well.
6. Incubate for 15 minutes at room temperature.
7. Discard the contents of the microwells and wash 3 times with 300 µL of wash solution.
8. Dispense 100 µL of TMB substrate solution into each well.
9. Incubate for 15 minutes at room temperature.

10. Add 100 µL of stop solution to each well of the modules.

11. Incubate for 5 minutes at room temperature.

12. Read the optical density at 450 nm (reference 600-690 nm) and calculate the results. The developed colour is stable for at least 30 minutes. Read during this time.

Data Analysis

Calculation of Results

✓ Validation

This test is only valid if the optical densities at 450 nm for calibrators / controls and the results for controls comply with the reference ranges indicated on the Certificate of analysis. If these quality control criteria are not met the assay run is invalid and should be repeated.

✓ Calculation of results

For quantitative results plot the optical density of each calibrator versus the calibrator concentration to create a calibration curve. The concentration of samples may then be estimated from the calibration curve by interpolation. Using data reduction software a 4-Parameter-Fit with lin-log coordinates for optical density and concentration is the data reduction method of choice.

Performance Characteristics

✓ Calibration

The assay system is calibrated against the internationally recognized reference sera from the CDC, Atlanta USA.

✓ Measuring Range

The calculation range of this ELISA assay is 0-200 U/mL.

✓ Expected values:

In a normal range study with samples from healthy blood donors the following ranges have been established with this ELISA assay: Cut-off 25 U/mL.

✓ Interpretation of results

Negative	< 15 U/mL
Borderline	15-25 U/mL
Positive	> 25 U/mL

✓ Linearity

Samples containing high levels of specific antibody were serially diluted in sample buffer to demonstrate the dynamic range of the assay and the upper / lower end linearity. Activity for each dilution was calculated form the calibration curve using a 4-Parameter-Fit with lin-log coordinates.

Sample	Dilution	Observed (U/mL)	Expected (U/mL)	O/E (%)
1	1:100	161.4	161.4	100
-	1:200	81.0	80.7	100
-	1:400	39.1	40.4	97
-	1:800	19.3	20.2	96
2	1:100	292.6	292.6	100
-	1:200	146.9	146.3	100
-	1:400	73.3	73.2	100
-	1:800	35.3	36.6	97

✓ Limit of detection

Functional sensitivity was determined to be: 1 U/mL

✓ Reproducibility

● Intra-assay precision: Coefficient of variation (CV) was calculated for each of three samples from the results of 24 determinations in a single run. Results for precision-within-assay are shown in the table below.

● Inter-assay precision: Coefficient of variation (CV) was calculated for each of three samples from the results of 6 determinations in 5 different runs. Results for run-to-run precision are shown in the table below.

Intra-Assay			Inter-Assay		
Sample	Mean U/mL	CV%	Sample	Mean U/mL	CV%
1	51.4	4.1	1	53.3	5.3
2	84.8	2.0	2	83.7	2.6
3	157.2	2.6	3	153.9	1.3

✓ Interfering Substances

No interference has been observed with haemolytic (up to 1000 mg/dL), lipemic (up to 3 g/dL triglycerides) sera or plasma, or bilirubin (up to 40 mg/dL) containing sera or plasma. Nor have any interfering effects been observed with the use of anticoagulants (Citrate, EDTA, Heparin). However for practical reasons it is recommended that grossly hemolyzed or lipemic samples should be avoided.

✓ Study Results

Study Population	n	n Pos	%
SLE	70	36	51.4
Rheumatoid Arthritis	20	3	15.0
Normal human sera	100	2	2.0

	Pos	Neg	
Pos	36	5	
Neg	34	115	
	70	120	190

Sensitivity: 51.4%

Specificity: 95.8%

Overall agreement: 79.5%

Resources

References

1. Alba P, Bento L, Bento L, Cuadrado MJ, Karim Y, Tungekar MF, Abbs I et al. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis 2003; 62 (6): 556-560.

2. Antico A, Platzgummer S, Bassetti D, Bizzaro N, Tozzoli R, Villalta D. Diagnosing systemic lupus erythematosus: new-generation immunoassays for measurement of anti-dsDNA antibodies are an effective alternative to the Farr technique and the Crithidia luciliae immunofluorescence test. Lupus 2010; 19 (8): 906-912.

3. Brouwer R, Hengstman GJ, Vree EW, Ehrfeld H, Bozic B, Ghirardello A et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001; 60 (2): 116-123.

4. Castro C, Gourley M. Diagnositc testing and interpretation of tests for autoimmunity. J Allergy Clin Immunol 2010; 125 (2 Suppl 2): S238-S247.

5. Defendenti C, Atzeni F, Spina MF, Grosso S, Cereda A, Guercilena G et al. Clincal and laboratory aspects of Ro/SSA-52 autoantibodies. Autoimmun Rev 2011; 10 (3): 150-154.

6. Eriksson C, Kokkonen H, Johansson M, Hallmans G, Wadell G, Rantapaa-Dahlqvist S. Autoantibodies predate the onset of Systemic Lupus Erythematosus in northern Sweden. Arthrits Research & Therapy 2011; 13 (1): R30.

7. Haugbro K, Nossent JC, Winkler T, Figenschau Y, Rekvig OP. Anti-dsDNA antibodies and diseases classification in ntinuclear antibody positive patient: the role of analytical diversity. Ann Rheum Dis JID – 0372355 2004; 63 (4): 386-394.

8. Ippolito A, Wallace DJ, Gladman D, FortinPR, Urowitz M, Werth V et al. Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositiity. Lupus 2011; 20 (3): 250-255.

9. Isenberg DA, Manson JJ, Ehrenstein MR, Rahman A. Fiftyyears of anti-ds DNA antibodies: are we approachingjourney's end? Rheumatology (Oxford) 2007; 46 (7): 1052-1056.

10. Kattah NH, Kattah MG, Utz PJ. The U1-snRNP complex: structural properties relatingto autoimmune pathogenesis in rheumatic diseases. Immunol Rev 2010; 233 (1): 126-145.

11. Kumar Y, Bhatia A, Minz RW. Antinuclear antinuclear antibodies and their detection methods in diagnosis of connective tissue diseases: a journey revisited. Diagn Pathol 2009; 4:1.

12. Meroni PL. Schur pH, ANA screening: an old test with new recommendations. Ann Rheum Dis 2010; 69: 1420-1422.

13. Petri M, Magder L. Classification criteria for systemic lupus erythematosus: a review. Lupus 2004; 13(11): 829-837.

14. Poole BD, Schneider RI, Guthridge JM, Velte CA, Reichlin M, Harley JB et al. Early targets of nuclear RNP humoral autoimmunity in human systemic lupus srythematosus. Arthritis Rheum 2009; 60(3): 848-859.

15. Putova I, Dostal C, Becvar R. Prevalence of antinucleosome antibodies by enzyme-linked immunosorbent assays in patients with systemic lupus erythematosus and other autoimmune systemic diseases. Ann NY Acad Sci 2007; 1109: 275-286.

16. Reveille JD. Predictive value of autoantibodies for activity of systemic lupus erythematosus. Lupus JID-9204265 2004; 13(5): 290-297.

17. Simon JA, Cabiedes J, Ortiz E, Alcocer-Varela J, Sanchez-Guerrero J. Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker. Rheumatology (Oxford) 2004; 43(2): 220-224.

18. Sinclair D, Saas M, Williams D, Hart M, Goswami R. Can an ELISA replace Immunofluorescence for the detection of anti-nuclear antibodies?—The routine use of anti-nuclear antibody screening ELISAs. Clin Lab 2007; 53(3-4): 183-191.

19. Tozzoli R, Bizzaro N, Tonutti E, Villalta D, Bassetti D, Manoni F et al. Guidelines for the laboratory use of autoantibody tests in the diagnosis and monitoring of autoimmune rheumatic disease. Am J Clin Pathol 2002; 117(2): 316-324.

20. Maidhof W., Hilias O. Lupus: an preview of the disease and management options. P T 2012' 37(4): 240-9.

21. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64(6):797-808.

Plate Layout

	1	2	3	4	5	6	7	8	9	10	11	12
A	Calibrators A	Sample 1										
B	Calibrators B	Sample 2										
C	Calibrators C	Sample 3										
D	Calibrators D											
E	Calibrators E											
F	Calibrators F											
G	Positive Control											
H	Negative Control											